

Resource Summary Report

Generated by [dkNET](#) on Jul 29, 2026

Brilliant Violet 785(TM) anti-human CD3

RRID:AB_11219196

Type: Antibody

Proper Citation

BioLegend Cat# 317329, RRID:AB_11219196

Antibody Information

URL: http://antibodyregistry.org/AB_11219196

Proper Citation: BioLegend Cat# 317329, RRID:AB_11219196

Target Antigen: CD3

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 785(TM) anti-human CD3

Description: This monoclonal targets CD3

Target Organism: human

Clone ID: Clone OKT3

Antibody ID: AB_11219196

Vendor: BioLegend

Catalog Number: 317329

Alternative Catalog Numbers: 317330

Record Creation Time: 20250820T015547+0000

Record Last Update: 20250820T121440+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 785(TM) anti-human CD3.

No alerts have been found for Brilliant Violet 785(TM) anti-human CD3.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 10 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Gramatica A, et al. (2025) EZH2 inhibition mitigates HIV immune evasion, reduces reservoir formation, and promotes skewing of CD8+ T cells toward less-exhausted phenotypes. Cell reports, 44(5), 115652.

Yang BH, et al. (2025) iPSC-derived trimodal T cells engineered with CAR, TCR, and hnCD16 modalities can overcome antigen escape in heterogeneous tumors. Cell reports. Medicine, 6(7), 102195.

Nesamari R, et al. (2024) Post-pandemic memory T cell response to SARS-CoV-2 is durable, broadly targeted, and cross-reactive to the hypermutated BA.2.86 variant. Cell host & microbe, 32(2), 162.

Martin-Gutierrez L, et al. (2024) Dysregulated lipid metabolism networks modulate T-cell function in people with relapsing-remitting multiple sclerosis. Clinical and experimental immunology, 217(2), 204.

Massenet-Regad L, et al. (2023) Large-scale analysis of cell-cell communication reveals angiogenin-dependent tumor progression in clear cell renal cell carcinoma. iScience, 26(12), 108367.

Gubser C, et al. (2023) GITR activation ex vivo impairs CD8 T cell function in people with HIV on antiretroviral therapy. iScience, 26(11), 108165.

Woan KV, et al. (2021) Harnessing features of adaptive NK cells to generate iPSC-derived NK cells for enhanced immunotherapy. Cell stem cell, 28(12), 2062.

Hinterbrandner M, et al. (2021) Tnfrsf4-expressing regulatory T cells promote immune escape of chronic myeloid leukemia stem cells. JCI insight, 6(23).

Nel I, et al. (2021) MAIT cell alterations in adults with recent-onset and long-term type 1 diabetes. Diabetologia, 64(10), 2306.

Neff CP, et al. (2018) Fecal Microbiota Composition Drives Immune Activation in HIV-infected Individuals. EBioMedicine, 30, 192.